Abstract 934P
Background
Locally advanced hypopharyngeal carcinoma (LAHC), an aggressive type of head and neck cancer (HNC), generally exhibits poor prognosis. Currently, The programmed death 1 inhibitors, implicated in antitumor activity, emerge as meaningful option in patients with recurrent or metastatic HNC, but the role of camrelizumab remains uncertain. Aim to determine effects and safety of induction therapy of camrelizumab plus TPF (docetaxel, cisplatin, and capecitabine) in LAHC.
Methods
In this single-arm, phase 2, prospective, and single-center trial, patients with T3-4aN0-3M0 LAHC received induction therapy for three cycles: camrelizumab 200 mg on day 1, docetaxel 75 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1-3, capecitabine 800 mg/m2 bid on day 1-14, every three weeks. Patients were assigned to radiotherapy and immunotherapy if they had a complete response or partial response (PR) or assigned to surgery and adjuvant (chemo)radiotherapy if they had stable disease (SD) or progressive disease that was defined by using a tumor volume evaluation system. Camrelizumab was maintained postradiotherapy and immunotherapy for a total of 18 doses. This trial was registered with ClinicalTrials.gov, No. NCT04156698 and is ongoing.
Results
Fifty-one patients were enrolled from May 21, 2020, to April 15, 2023, and the mean duration of follow-up was 16.5 ± 8.7 months. After induction therapy, 42 (82.4%) patients showed PR, and 9 (17.6%) showed SD. Treatment-related adverse events were recorded, leading to treatment suspension in 9 (17.6%) patients but no death. The most common adverse event was alopecia (100%), followed by RCCEP (90.2%), nausea/vomiting (84.3%), and fatigue (58.8%) in the induction therapy period. Twenty-six (51.0%) patients experienced grade 3 or 4 induction therapy-related adverse events. The two-year overall survival, progression-free survival, and laryngeal function preservation rates were 85.5%,72.8%, and 65.4%, respectively.
Conclusions
Camrelizumab plus TPF was well tolerated and demonstrated effective antitumor activity in LAHC, indicating future therapy options of camrelizumab as antitumor MAb for advanced HNC.
Clinical trial identification
NCT04156698.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This study was supported by the National Natural Science Foundation of China (81502343 and 81972529), Clinical Research Plan of SHDC (SHDC2020CR6011), the Science and Technology Commission of Shanghai Municipality (21Y11900100 and 19411961300).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12